IMR Press / FBL / Volume 2 / Issue 4 / DOI: 10.2741/A179

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Pathogenesis and treatment of HIV-1 infection: recent developments
Show Less
1 Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester NY 14642
2 Cancer Center, University of Rochester Medical Center, Rochester NY 14642
Academic Editor:Adriana Heguy
Front. Biosci. (Landmark Ed) 1997, 2(4), 147–159;
Published: 1 March 1997
(This article belongs to the Special Issue New and emerging targets for antiviral therapy)

Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of acquired immunodeficiency syndrome (AIDS) and is estimated to presently infect 24 million adults and 1.5 million children, worldwide. The pathogenesis of HIV-1-induced disease is complex and characterized by the interplay of both viral and host factors, which together determine the outcome of infection. An improved understanding of the pathogenic mechanisms of AIDS, combined with recent insights into the dynamics of viral infection, and the cellular co-receptors for HIV-1, may provide powerful new opportunities for therapeutic intervention against this virus.

Back to top